| 中文关键词: 食管肿瘤 靶向治疗 |
| 英文关键词:esophageal neoplasms targeted therapy |
| 基金项目:浙江省胸部肿瘤(肺、食管)诊治技术研究重点实验室(2011E10014) |
|
| 摘要点击次数: 2316 |
| 全文下载次数: 1235 |
| 中文摘要: |
| 摘 要：近年来由于手术、化疗和放疗技术的发展，食管癌的临床治疗有了很大的进展，但5年总生存率仍然较低。分子靶向治疗通过作用于肿瘤细胞特定靶点，在多种肿瘤中显示出了良好的疗效。在食管癌的治疗中也相继有一些药物进行了临床探索和应用。但在EGFR、HER2+、VEGF、c-MET、PI3K/Akt/mTOR等通路的靶向药物中多数Ⅱ、Ⅲ期临床研究结果令人失望。酪氨酸蛋白激酶抑制剂和血管内皮生长因子单克隆抗体在部分食管癌人群中显示出一定的生存受益。当然，还有一些新靶向药物（PD-1单克隆抗体、c-MET通路的单克隆抗体）研究结果值得期待。但目前大多数食管癌相关靶向研究均来自于西方人群的食管腺癌或食管胃结合部癌，国内数据相对缺乏，我们期待国内进行的尼妥珠单抗的临床研究能带来振奋人心的结果。 |
| 英文摘要: |
| Abstract：Despite recent advances in surgical techniques，chemotherapy and radiotherapy，the 5-year survival rate of esophageal cancer is still poor. Targeted therapy is a growing part of many cancer treatment regimens. A number of biologic agents targeting EGFR，HER2，VEGF，c-MET，PI3K/Akt/mTOR are being currently evaluated in Phase Ⅱ and Ⅲ clinical trials. Most of these trials were disappointing. Tyrosine kinase inhibitors and anti-vascular endothelial growth factor monoclonal antibodies have shown clinical benefit for a subset of patients. Of course there are some trials about the new targeted therapy compounds (anti-human PD-1 monoclonal antibody and anti-c-Met monoclonal antibody) are ongoing. Most of the results of these trials were from esophageal adenocarcinoma or gastroesophageal junction cancer. There are fewer data of Chinese patients with esophageal cancer，and we look forward the result about the trial of nimotuzumab in Chinese patients with esophageal cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
